Icon Plc (NASDAQ:ICLR - Free Report) - Analysts at Leerink Partnrs increased their FY2025 earnings per share (EPS) estimates for shares of Icon in a research note issued to investors on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now expects that the medical research company will earn $12.68 per share for the year, up from their previous forecast of $12.66. The consensus estimate for Icon's current full-year earnings is $13.38 per share. Leerink Partnrs also issued estimates for Icon's FY2026 earnings at $13.54 EPS and FY2027 earnings at $15.41 EPS.
Icon (NASDAQ:ICLR - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The medical research company reported $3.19 earnings per share for the quarter, topping the consensus estimate of $3.17 by $0.02. Icon had a return on equity of 11.46% and a net margin of 9.25%. The business had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.03 billion. During the same period in the prior year, the company posted $3.47 EPS. The firm's revenue for the quarter was down 4.3% compared to the same quarter last year.
Other research analysts also recently issued reports about the company. Truist Financial lowered their target price on Icon from $262.00 to $208.00 and set a "buy" rating for the company in a research report on Thursday, April 10th. TD Cowen downgraded Icon from a "buy" rating to a "hold" rating and lowered their target price for the company from $254.00 to $157.00 in a research report on Monday, April 14th. Citigroup lowered their target price on Icon from $290.00 to $215.00 and set a "buy" rating for the company in a research report on Monday, April 7th. Barclays lowered their target price on Icon from $165.00 to $155.00 and set an "equal weight" rating for the company in a research report on Friday, May 2nd. Finally, The Goldman Sachs Group lowered their target price on Icon from $180.00 to $160.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Eight investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $198.08.
Read Our Latest Research Report on Icon
Icon Price Performance
Shares of NASDAQ ICLR traded down $1.00 during midday trading on Friday, reaching $149.52. 1,174,925 shares of the stock traded hands, compared to its average volume of 1,258,863. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.27 and a quick ratio of 1.27. The stock has a market capitalization of $12.08 billion, a PE ratio of 16.29, a P/E/G ratio of 1.84 and a beta of 1.17. Icon has a one year low of $125.10 and a one year high of $347.72. The company's 50 day moving average is $140.25 and its 200 day moving average is $167.35.
Institutional Trading of Icon
Hedge funds and other institutional investors have recently bought and sold shares of the business. SVB Wealth LLC purchased a new stake in Icon in the first quarter worth $28,000. NBC Securities Inc. purchased a new stake in Icon in the first quarter worth $59,000. Bruce G. Allen Investments LLC increased its stake in Icon by 1,772.7% in the second quarter. Bruce G. Allen Investments LLC now owns 412 shares of the medical research company's stock worth $60,000 after purchasing an additional 390 shares during the period. Greykasell Wealth Strategies Inc. purchased a new position in shares of Icon during the first quarter valued at $69,000. Finally, Farther Finance Advisors LLC increased its stake in shares of Icon by 22.8% during the first quarter. Farther Finance Advisors LLC now owns 593 shares of the medical research company's stock valued at $99,000 after buying an additional 110 shares during the period. Hedge funds and other institutional investors own 95.61% of the company's stock.
About Icon
(
Get Free Report)
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
See Also
Before you consider Icon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Icon wasn't on the list.
While Icon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
